EDP Sciences logo
Submit your paper
Search
Menu
All issues Volume 37 / No 1 (March 2005) J Extra Corpor Technol, 37 1 (2005) 15-22 References
Free Access
Issue
J Extra Corpor Technol
Volume 37, Number 1, March 2005
Page(s) 15 - 22
DOI https://doi.org/10.1051/ject/200537015
Published online 15 March 2005
  1. Gerhardt MA, Greenberg CS, Slaughter TF, Smith MS. Factor XII deficiency and cardiopulmonary bypass. Anesthesiology. 1997;87:990–2. [CrossRef] [PubMed] [Google Scholar]
  2. Kelsey PR, Bottomley J, Grotte GJ, Maciver JE. Congenital factor XII deficiency: Successful open heart surgery and anticoagulation. Clin Lab Haematol. 1985;7:379–81. [CrossRef] [Google Scholar]
  3. Salmenpera M, Rasi V, Mattila S. Cardiopulmonary bypass in a patient with factor XII deficiency. Anesthesiology. 1991;75:539–41. [CrossRef] [PubMed] [Google Scholar]
  4. Moorman RM, Reynolds DS, Comunale ME. Management of cardiopulmonary bypass in a patient with congenital factor XII deficiency. J Cardiothorac Vasc Anesth. 1993;7:452–4. [CrossRef] [Google Scholar]
  5. Wood MK. Congenital factor XII deficiency and cardiopulmonary bypass. Ann Thorac Surg. 1994;58:1565. [CrossRef] [Google Scholar]
  6. Wallock M, Arentzen C. Factor XII deficiency and cardiopulmonary bypass. Perfusion. 1995;10:13–6. [CrossRef] [PubMed] [Google Scholar]
  7. Burman JF, Chung HI, Lane DA, Philippou H, Adami A, Lincoln JCR. Role of factor XII in thrombin generation and fibrinolysis during cardiopulmonary bypass. Lancet. 1994;344:1192–3. [CrossRef] [PubMed] [Google Scholar]
  8. Nahas C, Jones JW, Beall AC, Lafuente J, Irani M. Myocardial revascularization in a hemophiliac. Cardiovasc Surg. 1996;4:557–8. [CrossRef] [Google Scholar]
  9. Mackinlay N, Taper J, Renisson F, Rickard K. Cardiac surgery and catheterization in patients with haemophilia. Haemophilia. 2000;6:84–8. [CrossRef] [PubMed] [Google Scholar]
  10. Bretler DB, Levine PH. Factor concentrations for treatment of hemophilia: Which one to choose. Blood. 1989;73:2067–73. [CrossRef] [PubMed] [Google Scholar]
  11. Horrow JC. Desmopressin and antifibrinolytics. Int Anesthesiol Clin. 1990;28:230–6. [CrossRef] [PubMed] [Google Scholar]
  12. Koner O, Cetin G, Karaoglu K, Seren S, Bakay C. Fresh whole blood and immunoglobulin permit coronary artery bypass graft surgery in patients with idiopathic thrombocytopenic purpura. J Cardiothorac Vasc Anesth. 2001;15:483–4. [CrossRef] [Google Scholar]
  13. Christiansen S, Schmid C, Redmann K, et al. Preoperative immunoglobulin treatment in patients with Werlhof’s disease undergoing cardiac operation. Ann Thorac Surg. 2000;69:61–4. [CrossRef] [Google Scholar]
  14. Fujisawa K, Tani P, Piro L, McMillan R. The effect of therapy on platelet-associated autoantibody in chronic immune thrombocytopenic purpura. Blood. 1993;81:2872–3. [CrossRef] [PubMed] [Google Scholar]
  15. Nakamura K, Onitsuka T, Yano M, Nagahama H, Nakamura E, Matsuzaki Y. Nafamostat mesilate treatment during open heart operation in immune thrombocytopenic purpura. Ann Thorac Surg. 2000;70:2161–3. [CrossRef] [Google Scholar]
  16. Christiansen S, Rotker J, Roeder N, et al. Are patients with Werlhof’s disease at increased risk for bleeding complications with undergoing cardiac surgery? Eur J Cardiothorac Surg. 2000;18:353–6. [CrossRef] [PubMed] [Google Scholar]
  17. Simon TL, Akl BF, Murphy W. Controlled trial of routine administration of platelet concentrates in cardiopulmonary bypass surgery. Ann Thorac Surg. 1984;37:359–64. [CrossRef] [Google Scholar]
  18. Shulman G, McQuitty C, Vertrees RA, Conti VR. Acute normovolemic red cell exchange for cardiopulmonary bypass in sickle cell disease. Ann Thorac Surg. 1998;65:1444–6. [CrossRef] [Google Scholar]
  19. Black HA, Dearing JP. Exchange transfusion prior to cardiopulmonary bypass in sickle cell anemia. J ExtraCorp Technol. 1980;12:82–5. [Google Scholar]
  20. Balusundaram S, Duran CG, Al-Halees Z, Kassay M. Cardiopulmonary bypass in sickle cell anemia. Report of five cases. J Cardiovasc Surg. 1991;32:271–4. [Google Scholar]
  21. Chun PKC, Flannery EP, Bowen TE. Open-heart surgery in patients with hematologic disorders. Am Heart J. 1983;105:835–42. [CrossRef] [Google Scholar]
  22. Frimpong-Boateng K, Amoah AGB, Barwasser HM, Kallen C. Cardiopulmonary bypass in sickle cell anaemia without exchange transfusion. Eur J Cardiothorac Surg. 1998;14:527–9. [CrossRef] [Google Scholar]
  23. Comp PC, Esmon CT. Generation of fibrinolytic activity by infusion of activated protein C into dogs. J Clin Invest. 1981;68:1221–8. [CrossRef] [PubMed] [Google Scholar]
  24. Van Hinsbergh VWM, Bertina RM, van Wijngaarden A. Activated protein C decreases plasminogen activator-inhibitor activity in endothelial cell-conditioned medium. Blood. 1985;65:444–51. [CrossRef] [PubMed] [Google Scholar]
  25. Grocott HP, Clements F, Landolfo K. Coronoary artery bypass graft surgery in a patient with hereditary protein S deficiency. J Cardiothorac Vasc Anesth. 1996;10:915–7. [CrossRef] [Google Scholar]
  26. Engesser L. Hereditary protein S deficiency: clinical manifestations. Ann Intern Med. 1987;106:677–82. [CrossRef] [PubMed] [Google Scholar]
  27. Villacorta J, Guidon C, Kerbaul F, Mesana T, Gouin F. An intraoperative coronary artery bypass graft thrombosis in a patient with protein S deficiency. J Cardiothorac Vasc Anesth. 2001;15:805–7. [CrossRef] [Google Scholar]
  28. Topol EJ. Toward a new frontier in myocardial reperfusion therapy: emerging platelet preeminence. Circulation. 1998;97:211–8. [CrossRef] [PubMed] [Google Scholar]
  29. Alvarez JM. Emergency coronary bypass grafting for failed percutaneous coronary artery stenting: increased costs and platelet transfusion requirements after the use of abciximab. J Thorac Cardiovasc Surg. 1998;115:472–3. [CrossRef] [Google Scholar]
  30. Gammie JS, Zenati M, Kormos RL, Hattler BG, Pellegrini RV. Abciximab and excessive bleeding in patients undergoing emergency cardiac operations. Ann Thorac Surg. 1998;65:465–9. [CrossRef] [Google Scholar]
  31. Lefkovits J, Ivanhoe RJ, Califf RM. Effects of platelet glycoprotein receptor blockade by a chimeric monoclonal antibody (abciximab) on acute and six-month outcomes after percutaneous translunimal coronary angioplasty for acute myocardial infarction. EPIC investigators. Am J Cardiol. 1996;77:1045–51. [CrossRef] [Google Scholar]
  32. Silvestry SC, Smith PK. Current status of cardiac surgery in the abciximab-treated patient. Ann Thorac Surg. 2000;70:S12–9. [CrossRef] [Google Scholar]
  33. Dyke C, Gammie JS. Surgical implications of platelet glycoprotein IIb/IIIa inhibition. J Thorac Cardiovasc Surg. 1998;116:1083–4. [CrossRef] [Google Scholar]
  34. The EPILOG investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med. 1997;336:1689–96. [CrossRef] [PubMed] [Google Scholar]
  35. Gammies JS, Zenati M, Kormos RL, et al. Abciximab and excessive bleeding in patients undergoing emergency cardiac operations. Ann Thorac Surg. 1998;65:465–9. [CrossRef] [Google Scholar]
  36. Kereiakes DJ. Prophylactic platelet transfusion in abciximab treated patients requiring coronary bypass surgery (letter). Am J Cardiol. 1998;81:373. [Google Scholar]
  37. Weerasinghe A, Taylor KM. The platelet in cardiopulmonary bypass. Ann Thorac Surg. 1998;66:2145–52. [CrossRef] [Google Scholar]
  38. Poullis M, Manning R, Haskard D, Taylor K. Reopro removal during cardiopulmonary bypass using a hemoconcentrator. J Thorac Cardiovasc Surg. 1999;117:1032–4. [CrossRef] [Google Scholar]
  39. Van Norman GA, Gernsheimer T, Chandler WL, Cochran RP, Spiess BD. Indicator of fibrinolysis during cardiopulmonary bypass after exogenous antithrombin-III administration for acquired anti-thrombin III deficiency. J Cardiothorac Vasc Anesth. 1997;11:760–3. [CrossRef] [Google Scholar]
  40. Fourrier F, Chopin C, Huart J. Double-blind, placebo controlled trial of antithrombin III concentrates in septic shock with disseminated intravascular coagulation. Chest. 1993;104:882–8. [CrossRef] [PubMed] [Google Scholar]
  41. Lidon RM, Theroux P, Robitaille D, Runge I, Caron C, Goudemand J. Antithrombin III plasma activity during and after prolonged use of heparin in unstable angina. Throm Res. 1993;72:23–32. [CrossRef] [Google Scholar]
  42. Uppington J. Anesthetic management of patients with coagulation disorders. Int Anesthesiol Clin. 1985;23:125–40. [CrossRef] [PubMed] [Google Scholar]
  43. Piszkiewicz D, Apfelzweig R, Bourret L, et al. Inactivation of HIV in antithrombin III concentrate by pasteurization (letter). Transfusion. 1998;28:198–9. [Google Scholar]
  44. Menache D, O’Malley JP, Schorr JB, Wagner B, Willians C. Evaluation of the safety, recovery, half-life, and clinical efficacy of anti-thrombin III (human) in patients with hereditary antithrombin III deficiency. Blood. 1990;75:33–9. [CrossRef] [PubMed] [Google Scholar]
  45. Rossi M, Martinelli L, Storti S, et al. The role of antithrombin III in the perioperative management of the patient with unstable angina. Ann Thorac Surg. 1999;68:2231–6. [CrossRef] [Google Scholar]
  46. Baglin TP. Heparin induced thrombocytopenia thrombosis (HIT/T) syndrome: Diagnosis and treatment. J Clin Pathol. 2001;54:272–4. [CrossRef] [Google Scholar]
  47. Lindhoff-Last E, Gerdsen F, Ackermann H, Bauersachs R. Determination of heparin-platelet factor 4-IgG antibodies improves diagnosis of heparin-induced thrombocytopenia. Br J Haematol. 2001;113:886–90. [CrossRef] [Google Scholar]
  48. Amiral J, Bridey F, Wolf M, et al. Antibodies to macromolecular platelet factor 4-heparin complexes in heparin-induced thrombocytopenia: A study of 44 cases. Thromb Haemost. 1995;73:21–8. [Google Scholar]
  49. Follis F, Schmidt CA. Cardiopulmonary bypass in patients with heparin-induced thrombocytopenia and thrombosis. Ann Thorac Surg. 2000;70:2173–81. [CrossRef] [Google Scholar]
  50. Mollison PL, Engelfriet CP, Contreras M Blood Transfusion in Clinical Medicine. 9th ed. Oxford, England: Blackwell Scientific; 1993. [Google Scholar]
  51. Potzsch B, Klovekorn WP. Use of heparin during cardiopulmonary bypass in patients with a history of heparin-induced thrombobytopenia. N Engl J Med. 2001;343:515. [Google Scholar]
  52. Frederiksen JW. Cardiopulmonary bypass in human: bypass unfractioned heparin. Ann Thorac Surg. 2000;70:1434–43. [CrossRef] [Google Scholar]
  53. Gouault-Heilmann M, Huet Y, Contant G, Payen D, Bloch G, Rapin M. Cardiopulmonary bypass with a low-molecular weight heparin fraction. Lancet. 1983;2:1374. [CrossRef] [Google Scholar]
  54. Prifti E, Bonacchi M, Leacche M, Miraldi F. Undergoing cardiopulmonary bypass using enoxaparin only during a cardiac transplantation procedure. Eur J Cardiothorac Surg. 2000;17:760–2. [CrossRef] [Google Scholar]
  55. Arnoletti JP, Whitman GJR. Heparin-induced thrombocytopenia in coronary bypass surgery. Ann Thorac Surg. 1999;68:576–8. [CrossRef] [Google Scholar]
  56. Magnani HN, Beijering RJR, et al. Organ anticoagulation for cardiopulmonary bypass in patients with heparin-induced thrombocytopenia. In Pifarre R, ed. New Anticoagulants for the Cardiovascular Patient. Philadelphia: Hanley & Belfus; 1997; 487–500. [Google Scholar]
  57. Zulys VJ, Teasdale SJ, Michel ER, et al. Ancrod as an alternative to heparin anticoagulation for cardiopulmonary bypass. Anesthesiology. 1989;71:870–7. [CrossRef] [PubMed] [Google Scholar]
  58. Potzsch B, Iversen S, et al. Recombinant hirudin as an anticoagulant in open-heart surgery: A case report. Ann Hematol. 1994;68:A53. [Google Scholar]
  59. Newman PM, Swanson RL, Chong BH. Heparin-induced thrombocytopenia: IgG binding to PF4-heparin complexes in the fluid phase and cross-reactivity with low molecular weight heparin and heparinoid. Throm Haemost. 1998;80:292–7. [CrossRef] [PubMed] [Google Scholar]
  60. Nurmohamed MT, Berckmans RJ, Morrien-Salomons WM, et al. Monitoring anticoagulant therapy by activated partial thromboplastin time: Hirudin assessment—an evaluation of native blood and plasma assays. Throm Haemost. 1994;72:685–92. [CrossRef] [PubMed] [Google Scholar]
  61. Potzsch B, Madlener K, Seelig C, Riess CF, Greinacher A, Muller-Berghaus G. Monitoring of r-hirudin anticoagulation during cardiopulmonary bypass: Assessment of the whole blood ecarin clotting time. Thromb Haemost. 1997;77:920–5. [Google Scholar]
  62. Konkle BA, Bauer TL, Arepally G, et al. Heparin-induced thrombocytopenia: bovine versus porcine Heparin in cardiopulmonary bypass surgery. Ann Thorac Surg. 2001;71:1920–4. [CrossRef] [Google Scholar]
  63. Gordon G, Rastegar H, Schumann R, Deiss-Shrem J, Denman W. Successful use of bivalirudin for cardiopulmonary bypass in a patient with heparin-induced thrombocytopenia. J Cardiothorac Vasc Anesth. 2003;17:632–5. [CrossRef] [Google Scholar]
  64. Davis Z, Anderson R, Short D, Garber D, Valgiusti A. Favorable outcome with bivalirudin anticoagulation during cardiopulmonary bypass. Ann Thorac Surg. 2003;75:264–5. [CrossRef] [Google Scholar]
  65. Vasquez JC, Vichiendilokkul A, Mahmood S, Baciewicz FAJr. Anticoagulation with bivalirudin during cardiopulmonary bypass in cardiac surgery. Ann Thorac Surg. 2002;74:2177–9. [CrossRef] [Google Scholar]
  66. Merry AF. Bivalirudin, blood loss, and graft patency in coronary artery bypass surgery. Semin Thromb Hemost. 2004;36:337–46. [CrossRef] [PubMed] [Google Scholar]
  67. Kakkar AK, Williamson RCN. Prevention of VET in cancer patients. Semin Thromb Hemost. 1999;25:239–43. [Google Scholar]
  68. Clagett GP, Reisch JS. Prevention of VET in general surgical patients: results of a meta-analysis. Ann Surg. 1998;208:227–40. [Google Scholar]
  69. Sutherland DE, Weitz IC, Liebman HA. Thromboembolic complications of cancer: Epidemiology, pathogenesis, diagnosis and treatment. Am J Hemat. 2003;72:43–52. [CrossRef] [PubMed] [Google Scholar]
  70. Roger LR. Cerebrovascular complications in cancer patients. Neurologic Clinics. 2003;21:167–92. [CrossRef] [PubMed] [Google Scholar]
  71. Rao LVM. Tissue factor as a tumor procoagulant. Cancer Metastasis Rev. 1992;11:249–66. [CrossRef] [PubMed] [Google Scholar]
  72. Falanga A, Gordon SG. Isolation and characterization of cancer procoagulant: A cysteine proteinase form malignant tissue. Biochemistry. 1985;24:5558–67. [CrossRef] [PubMed] [Google Scholar]
  73. Dashmahapatra KS, Cheung NK, Spillert C, Lazaro E. An assessment of monocyte procoagulant activity in patients with solid tumor. J Surg Res. 1987;43:158–63. [CrossRef] [Google Scholar]
  74. Falanga A, Rickles FR. Pathophysiology of thrombophilic state in the cancer patient. Semin Thromb Haemost. 1992;25:173–82. [Google Scholar]
  75. Kakkar AK, DeRuvo N, Chinswangwatanakul V, Tebbutt S, Williamson RCN. Extrinsic-pathway activation in cancer with high factor VIIa and tissue factor. Lancet. 1995;346:1004–5. [CrossRef] [PubMed] [Google Scholar]
  76. Nijziel MR, Oerle RV, Christella M, et al. Acquired resistance to activated protein C in breast cancer patients. Br J Haematol. 2003;120:117–22. [CrossRef] [Google Scholar]
  77. Chaturvedi S, Ansell J, Recht L. Should cerebral ischemic events in cancer patients be considered a manifestation of hypercoagulability? Stroke. 1994;25:1215–8. [CrossRef] [PubMed] [Google Scholar]
  78. Hedderich GS, O’Connor RJ, Reid EC, Mulder DS. Caval tumor thrombus complicating renal cell carcinoma: A surgical challenge. Surgery. 1988;102:614–9. [Google Scholar]
  79. Harvey RL, Mychaskiw G, Sachdev V, Heath BJ. Isolated cardiac metastasis of cervical carcinoma presenting as disseminated intravascular coagulopathy. J Reprod Med. 2000;45:603–6. [Google Scholar]
  80. Milligan NS, Edwards JC, Monro JL, Atwell JD. Excision of giant haemangioma in the newborn using hypothermia and cardiopulmonary bypass. Anaesthesia. 1985;40:875–8. [CrossRef] [PubMed] [Google Scholar]
  81. Stewart JR, Carey JA, McDougal WS, Merrill WH, Koch MO, Bender HW. Cavoatrial tumor thrombectomy using cardiopulmonary bypass without circulatory arrest. Ann Thorac Surg. 1991;51:717–22. [CrossRef] [Google Scholar]
  82. Chun PKC, Flannery EP, Bowen TE. Open-heart surgery in patients with hematologic disorders. Am Heart J. 1983;105:835–42. [CrossRef] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.